Short Interest in Sysmex Corporation ADR (OTCMKTS:SSMXY) Expands By 601.3%

Sysmex Corporation ADR (OTCMKTS:SSMXY) was the recipient of a significant growth in short interest during the month of December. As of December 31st, there was short interest totaling 277,294 shares, a growth of 601.3% from the December 15th total of 39,540 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average trading volume of 670,805 shares, the short-interest ratio is currently 0.4 days. Based on an average trading volume of 670,805 shares, the short-interest ratio is currently 0.4 days. Approximately 0.0% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

Separately, The Goldman Sachs Group raised shares of Sysmex from a “hold” rating to a “buy” rating in a research note on Thursday, October 9th. One analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy”.

Sysmex Trading Up 0.9%

OTCMKTS:SSMXY traded up $0.09 on Monday, reaching $10.19. 295,770 shares of the stock traded hands, compared to its average volume of 433,793. The company has a current ratio of 3.34, a quick ratio of 2.49 and a debt-to-equity ratio of 0.11. Sysmex has a 1-year low of $9.00 and a 1-year high of $20.31. The company’s 50 day moving average is $9.87 and its 200-day moving average is $12.52. The firm has a market capitalization of $6.41 billion, a price-to-earnings ratio of 20.38 and a beta of 1.13.

Sysmex (OTCMKTS:SSMXY) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $0.16 EPS for the quarter, meeting analysts’ consensus estimates of $0.16. Sysmex had a net margin of 9.32% and a return on equity of 9.86%. The company had revenue of $826.60 million for the quarter, compared to analyst estimates of $880.80 million. Equities research analysts anticipate that Sysmex will post 0.57 EPS for the current fiscal year.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.